DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/x8l9fz/jakstat) has announced the addition of the "Jak-STAT Signaling Pathway in Oncology Drug Pipeline Update 2015" report to their offering.
The Janus kinase/signal transducers and activators of transcription (JAK/STAT) pathway is one of a handful of pleiotropic cascades used to transduce a multitude of signals for development and homeostasis in animals, from humans to flies. In mammals, the JAK/STAT pathway is the principal signaling mechanism for a wide array of cytokines and growth factors.
There are today 261 companies plus partners developing 333 Jak-STAT signaling pathway targeting drugs in 931 developmental projects in cancer. In addition, there are 7 suspended drugs and the accumulated number of ceased drugs over the last years amount to another 135 drugs.
Jak-Stat Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 182 different targets. All included targets have been cross-referenced for the presence of mutations associated with human cancer.
To date 171 out of the 175 studied drug targets so far have been recorded with somatic mutations. The software application lets you narrow in on these mutations and links out to the mutational analysis for each of the drug targets for detailed information. All drugs targets are further categorized on in the software application by 40 classifications of molecular function and with pathway referrals to BioCarta, KEGG, NCI-Nature and NetPath.
Pipeline Breakdown According to Number of Drugs
- Marketed - 79
- Pre-registration - 3
- Phase III - 27
- Phase II - 90
- Phase I - 106
- Preclinical - 140
- No Data - 6
- Suspended - 7
- Ceased - 135
Delivery Format: Desktop App plus Online Access to Updates (One Year)
For more information visit http://www.researchandmarkets.com/research/x8l9fz/jakstat